BRIEF-Instil Bio And Immuneonco Announce Global Registrational Strategy For Pd-L1xvegf Bispecific Antibody, Syn-2510/Imm2510, In Non-Small Cell Lung Cancer And Triple-Negative Breast Cancer

Reuters09-16

Sept 16 (Reuters) - ImmuneOnco Biopharmaceuticals Shanghai Inc :

* INSTIL BIO AND IMMUNEONCO ANNOUNCE GLOBAL REGISTRATIONAL STRATEGY FOR PD-L1XVEGF BISPECIFIC ANTIBODY, SYN-2510/IMM2510, IN NON-SMALL CELL LUNG CANCER AND TRIPLE-NEGATIVE BREAST CANCER

* INSTIL BIO INC - INITIATION OF PHASE 1B/2 IMM2510/SYN-2510 + CHEMOTHERAPY COMBINATION IN FIRST-LINE NSCLC ANTICIPATED IN LATE 2024 IN CHINA

* INSTIL BIO INC - INITIATION OF PHASE 1B/2 IMM2510/SYN-2510 + CHEMOTHERAPY COMBINATION IN FIRST-LINE TNBC ANTICIPATED IN EARLY 2025 IN CHINA

* INSTIL BIO INC - US IND SUBMISSION FOR SYN-2510 TARGETED IN LATE 2024, STARTING WITH PHASE 2 TRIAL OF SYN-2510 MONOTHERAPY IN SECOND-LINE NSCLC

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2467181997?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-16 19:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2467181997","market":"sh","top_or_hot":-1,"title":"BRIEF-Instil Bio And Immuneonco Announce Global Registrational Strategy For Pd-L1xvegf Bispecific Antibody, Syn-2510/Imm2510, In Non-Small Cell Lung Cancer And Triple-Negative Breast Cancer","media":"Reuters","content":"<html><body><p>Sept 16 (Reuters) - ImmuneOnco Biopharmaceuticals Shanghai Inc   :</p><p>   * INSTIL BIO AND IMMUNEONCO ANNOUNCE GLOBAL REGISTRATIONAL STRATEGY FOR PD-L1XVEGF BISPECIFIC ANTIBODY, SYN-2510/IMM2510, IN NON-SMALL CELL LUNG CANCER AND TRIPLE-NEGATIVE BREAST CANCER</p><p>   * INSTIL BIO INC - INITIATION OF PHASE 1B/2 IMM2510/SYN-2510 + CHEMOTHERAPY COMBINATION IN FIRST-LINE NSCLC ANTICIPATED IN LATE 2024 IN CHINA</p><p>   * INSTIL BIO INC - INITIATION OF PHASE 1B/2 IMM2510/SYN-2510 + CHEMOTHERAPY COMBINATION IN FIRST-LINE TNBC ANTICIPATED IN EARLY 2025 IN CHINA</p><p>   * INSTIL BIO INC - US IND SUBMISSION FOR SYN-2510 TARGETED IN LATE 2024, STARTING WITH PHASE 2 TRIAL OF SYN-2510 MONOTHERAPY IN SECOND-LINE NSCLC</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Instil Bio And Immuneonco Announce Global Registrational Strategy For Pd-L1xvegf Bispecific Antibody, Syn-2510/Imm2510, In Non-Small Cell Lung Cancer And Triple-Negative Breast Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Instil Bio And Immuneonco Announce Global Registrational Strategy For Pd-L1xvegf Bispecific Antibody, Syn-2510/Imm2510, In Non-Small Cell Lung Cancer And Triple-Negative Breast Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-16 19:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sept 16 (Reuters) - ImmuneOnco Biopharmaceuticals Shanghai Inc   :   * INSTIL BIO AND IMMUNEONCO ANNOUNCE GLOBAL REGISTRATIONAL STRATEGY FOR PD-L1XVEGF BISPECIFIC ANTIBODY, SYN-2510/IMM2510, IN NON-...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2467181997","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2467181997","pubTimestamp":1726486075,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Sept 16  - ImmuneOnco Biopharmaceuticals Shanghai Inc   :   * INSTIL BIO AND IMMUNEONCO ANNOUNCE GLOBAL REGISTRATIONAL STRATEGY FOR PD-L1XVEGF BISPECIFIC ANTIBODY, SYN-2510/IMM2510, IN NON-SMALL CELL LUNG CANCER AND TRIPLE-NEGATIVE BREAST CANCER   * INSTIL BIO INC - INITIATION OF PHASE 1B/2 IMM2510/SYN-2510 + CHEMOTHERAPY COMBINATION IN FIRST-LINE NSCLC ANTICIPATED IN LATE 2024 IN CHINA   * INSTIL BIO INC - INITIATION OF PHASE 1B/2 IMM2510/SYN-2510 + CHEMOTHERAPY COMBINATION IN FIRST-LINE TNBC ANTICIPATED IN EARLY 2025 IN CHINA   * INSTIL BIO INC - US IND SUBMISSION FOR SYN-2510 TARGETED IN LATE 2024, STARTING WITH PHASE 2 TRIAL OF SYN-2510 MONOTHERAPY IN SECOND-LINE NSCLCSource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","BK4505":"高瓴资本持仓","BK4139":"生物科技","01541":"宜明昂科-B"},"translate_title":"BRIEF-Instil Bio和Immuneonco宣布Pd-L1xvegf双特异性抗体Syn-2510/Imm2510在非小细胞肺癌和三阴性乳腺癌中的全球注册策略","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01541":0.9},"content_text":"Sept 16 (Reuters) - ImmuneOnco Biopharmaceuticals Shanghai Inc   :   * INSTIL BIO AND IMMUNEONCO ANNOUNCE GLOBAL REGISTRATIONAL STRATEGY FOR PD-L1XVEGF BISPECIFIC ANTIBODY, SYN-2510/IMM2510, IN NON-SMALL CELL LUNG CANCER AND TRIPLE-NEGATIVE BREAST CANCER   * INSTIL BIO INC - INITIATION OF PHASE 1B/2 IMM2510/SYN-2510 + CHEMOTHERAPY COMBINATION IN FIRST-LINE NSCLC ANTICIPATED IN LATE 2024 IN CHINA   * INSTIL BIO INC - INITIATION OF PHASE 1B/2 IMM2510/SYN-2510 + CHEMOTHERAPY COMBINATION IN FIRST-LINE TNBC ANTICIPATED IN EARLY 2025 IN CHINA   * INSTIL BIO INC - US IND SUBMISSION FOR SYN-2510 TARGETED IN LATE 2024, STARTING WITH PHASE 2 TRIAL OF SYN-2510 MONOTHERAPY IN SECOND-LINE NSCLCSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2467181997"}